These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 25616444

  • 21. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K, Tiamkao S, Pongchaiyakul C, Pulkes T.
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [Abstract] [Full Text] [Related]

  • 22. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
    Amboni M, Stocchi F, Abbruzzese G, Morgante L, Onofrj M, Ruggieri S, Tinazzi M, Zappia M, Attar M, Colombo D, Simoni L, Ori A, Barone P, Antonini A, DEEP Study Group.
    Parkinsonism Relat Disord; 2015 Jun; 21(6):644-9. PubMed ID: 25899545
    [Abstract] [Full Text] [Related]

  • 23. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 Jun; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 24. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    Simonson W, Hauser RA, Schapira AH.
    Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
    [Abstract] [Full Text] [Related]

  • 25. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T, Uchiyama T, Higuchi Y, Asahina M, Hirano S, Yamanaka Y, Kuwabara S.
    PLoS One; 2015 Nov; 10(9):e0138462. PubMed ID: 26394059
    [Abstract] [Full Text] [Related]

  • 26. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?
    Bareš M, Rektorová I, Jech R, Farníková K, Roth J, Růžička E, Kaňovský P, Rektor I, Pavlík T, Uhlířová L, Vydlák J.
    J Neural Transm (Vienna); 2012 Mar; 119(3):373-80. PubMed ID: 21769622
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease.
    Stacy M, Hauser R.
    J Neural Transm (Vienna); 2007 Feb; 114(2):211-7. PubMed ID: 16897594
    [Abstract] [Full Text] [Related]

  • 30. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W, Gołąb-Janowska M, Safranow K, Rotter I, Amernik K, Honczarenko K, Nowacki P.
    Neurol Neurochir Pol; 2015 Feb; 49(5):302-6. PubMed ID: 26377981
    [Abstract] [Full Text] [Related]

  • 31. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment.
    Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E.
    Clin Neuropharmacol; 2006 Feb; 29(6):312-21. PubMed ID: 17095894
    [Abstract] [Full Text] [Related]

  • 32. Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations.
    Melo LM, Chien HF, Barbosa ER.
    Arq Neuropsiquiatr; 2010 Aug; 68(4):506-10. PubMed ID: 20730301
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease.
    Rana AQ, Depradine J.
    West Indian Med J; 2011 Mar; 60(2):223-4. PubMed ID: 21942133
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M, Leinonen M, Poewe W.
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [Abstract] [Full Text] [Related]

  • 37. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [Abstract] [Full Text] [Related]

  • 38. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
    Iansek R, Danoudis M.
    Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hand coordination as a quantitative measure of motor abnormality and therapeutic response in Parkinson's disease.
    Benice TS, Lou JS, Eaton R, Nutt J.
    Clin Neurophysiol; 2007 Aug; 118(8):1776-84. PubMed ID: 17576094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.